Aprepitant- and Olanzapine- Containing Anti-emetic Regimens With High Dose Melphalan

PHASE3CompletedINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

September 23, 2017

Primary Completion Date

December 30, 2021

Study Completion Date

December 1, 2022

Conditions
NauseaVomiting
Interventions
DRUG

o Aprepitant 125 mg orally one hour prior to chemotherapy on Day -1 and 80 mg orally on Days 0 and +1

Add aprepitant to anti-emetic regimen

DRUG

Olanzapine10 mg orally daily on Days -1,0,+1 and +2

add olanzapine to anti-emetic regimen

DRUG

Aprepitant plus Olanzapine

add aprepitant and olanzapine to anti-emetic regimen

Trial Locations (1)

60612

Rush University Medical Center, Chicago

All Listed Sponsors
lead

Rush University Medical Center

OTHER

NCT02939287 - Aprepitant- and Olanzapine- Containing Anti-emetic Regimens With High Dose Melphalan | Biotech Hunter | Biotech Hunter